TransMedics Group (TMDX) Scheduled to Post Quarterly Earnings on Monday

TransMedics Group (NASDAQ:TMDX) is scheduled to be issuing its quarterly earnings data after the market closes on Monday, October 28th. Analysts expect the company to announce earnings of $0.28 per share for the quarter. TransMedics Group has set its FY 2024 guidance at EPS.Persons interested in participating in the company’s earnings conference call can do so using this link.

TransMedics Group (NASDAQ:TMDX) last released its quarterly earnings results on Wednesday, July 31st. The company reported $0.35 earnings per share for the quarter, topping the consensus estimate of $0.21 by $0.14. The business had revenue of $114.30 million for the quarter, compared to the consensus estimate of $98.84 million. TransMedics Group had a net margin of 0.84% and a return on equity of 15.98%. The company’s quarterly revenue was up 117.7% on a year-over-year basis. During the same period last year, the firm earned ($0.03) earnings per share. On average, analysts expect TransMedics Group to post $1 EPS for the current fiscal year and $2 EPS for the next fiscal year.

TransMedics Group Trading Up 2.6 %

NASDAQ:TMDX opened at $125.17 on Friday. The company has a debt-to-equity ratio of 2.67, a current ratio of 9.37 and a quick ratio of 8.48. The firm has a market capitalization of $4.12 billion, a price-to-earnings ratio of -368.15 and a beta of 1.99. TransMedics Group has a one year low of $36.42 and a one year high of $177.37. The business has a fifty day moving average price of $148.39 and a 200-day moving average price of $139.33.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on the company. Needham & Company LLC initiated coverage on TransMedics Group in a research note on Wednesday, August 21st. They issued a “buy” rating and a $208.00 price objective on the stock. Oppenheimer lifted their price target on shares of TransMedics Group from $125.00 to $200.00 and gave the company an “outperform” rating in a report on Thursday, August 1st. Baird R W raised shares of TransMedics Group to a “strong-buy” rating in a research note on Tuesday, September 24th. Robert W. Baird initiated coverage on shares of TransMedics Group in a research note on Tuesday, September 24th. They set an “outperform” rating and a $200.00 target price on the stock. Finally, Stephens increased their price target on TransMedics Group from $151.00 to $178.00 and gave the stock an “overweight” rating in a research note on Friday, August 2nd. One research analyst has rated the stock with a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $174.30.

Insider Transactions at TransMedics Group

In other news, insider Tamer I. Khayal sold 2,958 shares of the company’s stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $156.77, for a total transaction of $463,725.66. Following the sale, the insider now directly owns 20,843 shares of the company’s stock, valued at $3,267,557.11. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other TransMedics Group news, insider Anil P. Ranganath sold 4,289 shares of the business’s stock in a transaction that occurred on Wednesday, August 7th. The stock was sold at an average price of $152.20, for a total transaction of $652,785.80. Following the sale, the insider now directly owns 8,893 shares of the company’s stock, valued at $1,353,514.60. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Tamer I. Khayal sold 2,958 shares of the company’s stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $156.77, for a total value of $463,725.66. Following the sale, the insider now owns 20,843 shares in the company, valued at approximately $3,267,557.11. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 64,205 shares of company stock valued at $9,981,907. 7.00% of the stock is currently owned by insiders.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.